Adolescents taking a selfie together
Adolescents taking a selfie together

The persons depicted are models used
for illustrative purposes only.

The persons depicted are models used for illustrative purposes only.

...IT’S TIME FOR A BOOSTER DOSE

  • MENVEO 1-vial presentation is approved for use in individuals 10 through 55 years of age1
  • MENVEO 2-vial presentation is approved for use in individuals 2 months through 55 years of age1

ADOLESCENTS ARE CONSTANTLY CHANGING—BUT THEIR NEED FOR VACCINATION DOES NOT

ADOLESCENTS ARE CONSTANTLY CHANGING
BUT THEIR NEED FOR VACCINATION DOES NOT

While your patients may have received a primary dose of a meningitis ACWY (MenACWY) vaccine at age 11-12, it's time to follow up and fulfill the CDC recommendations for adolescents—with a booster dose at 16 years of age.2,3

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

INDICATION

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 in individuals 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections.

 -

Icon: clipboard

Be sure to check your records

According to 2021 CDC survey data, 91% of 17-year-olds had received a single dose of a MenACWY vaccine—
but only 60% had received a booster dose.4 Are you doing all you can to help protect your patients?

According to 2021 CDC survey data, 91% of 17-year-olds had received a single dose of a MenACWY vaccine—but only 60% had received a booster dose.4 Are you doing all you can to help protect your patients?

 -

FDA-approved MENVEO dosing for adolescents and adults

PRIMARY
VACCINATION

SINGLE DOSE in adolescents and adults
aged 10 through 55 years1

SINGLE DOSE in adolescents and adults
aged 10 through 55 years1

BOOSTER
VACCINATION

SINGLE BOOSTER dose in individuals 15
through 55 years of age who are at continued
risk of meningococcal disease, at least 4
years after a prior dose of a MenACWY
vaccine1

SINGLE BOOSTER dose in individuals 15
through 55 years of age who are at continued
risk of meningococcal disease, at least 4
years after a prior dose of a MenACWY
vaccine1

 -

Icon: shopping cart

Order MENVEO

Are your patients missing their MenACWY booster dose?

Visit the GSK portal or contact your wholesaler/distributor to place an order today.

Are your patients missing their MenACWY booster dose?

Visit the GSK portal or contact your wholesaler/distributor to place an order today.

 -

What you can do

Icon: important information

LEARN MORE
about meningococcal disease and what
you can do to help prevent it.
sd

Icon: bar chart with data

HELP PROTECT
appropriate adolescent patients with a
primary AND booster dose of MENVEO as recommended by the CDC.

HELP PROTECT
appropriate adolescent patients with a
primary
AND booster dose of MENVEO as recommended by the CDC.

Icon: history with experience

DISCOVER THE HISTORY
of global heritage.
primary and booster dose of menveo
sdf

Vaccination may not protect all recipients.

CDC=Centers for Disease Control and Prevention.